{"transactions":[{"id":4636432,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-06T21:53:54.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":558,"price":20.7169,"value":11560.0302,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of\nrestricted stock units granted by the Issuer."}],"balance_after":80484,"source":{"system":"sec-edgar","filing":"0001919246-26-000130","document":"wk-form4_1791323632.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1919246/000191924626000130/wk-form4_1791323632.xml","form_type":"4"}},{"id":713370,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T21:03:57.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":24,"price":27.3254,"value":655.8096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of\nrestricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock\nsold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the\ntransaction was effected."}],"balance_after":81042,"source":{"system":"sec-edgar","filing":"0001919246-26-000102","document":"wk-form4_1783458235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000102/wk-form4_1783458235.xml","form_type":"4"}},{"id":713369,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T21:03:57.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":534,"price":26.0303,"value":13900.1802,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of\nrestricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $25.58 to $26.24. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock\nsold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the\ntransaction was effected."}],"balance_after":81066,"source":{"system":"sec-edgar","filing":"0001919246-26-000102","document":"wk-form4_1783458235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000102/wk-form4_1783458235.xml","form_type":"4"}},{"id":733281,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T21:25:09.000Z","date":"2026-06-15","kind":"sale","planned":true,"acquired":false,"shares":59,"price":27.9403,"value":1648.4777,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of\nrestricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $27.92 to $28.00. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock\nsold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the\ntransaction was effected."}],"balance_after":81600,"source":{"system":"sec-edgar","filing":"0001919246-26-000093","document":"wk-form4_1781731506.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000093/wk-form4_1781731506.xml","form_type":"4"}},{"id":733280,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T21:25:09.000Z","date":"2026-06-15","kind":"sale","planned":true,"acquired":false,"shares":224,"price":27.1245,"value":6075.888,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of\nrestricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $26.71 to $27.44. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock\nsold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the\ntransaction was effected."}],"balance_after":81659,"source":{"system":"sec-edgar","filing":"0001919246-26-000093","document":"wk-form4_1781731506.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000093/wk-form4_1781731506.xml","form_type":"4"}},{"id":774294,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-18T22:11:12.000Z","date":"2026-05-14","kind":"tax_withholding","planned":true,"acquired":false,"shares":144,"price":27.007,"value":3889.008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $27.00 to $27.0101. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":81883,"source":{"system":"sec-edgar","filing":"0001919246-26-000073","document":"wk-form4_1779142269.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000073/wk-form4_1779142269.xml","form_type":"4"}},{"id":814156,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-06T21:03:04.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":265,"price":21.3612,"value":5660.718,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":82027,"source":{"system":"sec-edgar","filing":"0001919246-26-000054","document":"wk-form4_1775509382.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000054/wk-form4_1775509382.xml","form_type":"4"}},{"id":814155,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-06T21:03:04.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":293,"price":20.5121,"value":6010.0453,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":82292,"source":{"system":"sec-edgar","filing":"0001919246-26-000054","document":"wk-form4_1775509382.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000054/wk-form4_1775509382.xml","form_type":"4"}},{"id":822492,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:45:39.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":19108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"From June 18, 2024 to July 7, 2025, the reporting person  filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the \"Original Form 4s\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."}],"balance_after":82585,"source":{"system":"sec-edgar","filing":"0001919246-26-000047","document":"wk-form4a_1775079936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000047/wk-form4a_1775079936.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822491,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:45:39.000Z","date":"2024-11-13","kind":"grant","planned":false,"acquired":true,"shares":2454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"From June 18, 2024 to July 7, 2025, the reporting person  filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the \"Original Form 4s\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":63477,"source":{"system":"sec-edgar","filing":"0001919246-26-000047","document":"wk-form4a_1775079936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000047/wk-form4a_1775079936.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822490,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:45:39.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":6450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"From June 18, 2024 to July 7, 2025, the reporting person  filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the \"Original Form 4s\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":61023,"source":{"system":"sec-edgar","filing":"0001919246-26-000047","document":"wk-form4a_1775079936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000047/wk-form4a_1775079936.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":986573,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T17:37:02.000Z","date":"2025-11-25","kind":"sale","planned":false,"acquired":false,"shares":2000,"price":28.005,"value":56010.0,"ownership":{"direct":false,"nature":"By Balmoral Financial Group LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001753926-25-001831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001831/ownership.xml","form_type":"4"}},{"id":986572,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T17:37:02.000Z","date":"2025-11-25","kind":"sale","planned":false,"acquired":false,"shares":1,"price":28.5,"value":28.5,"ownership":{"direct":false,"nature":"By Balmoral Financial Group LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001753926-25-001831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001831/ownership.xml","form_type":"4"}},{"id":986571,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T17:37:02.000Z","date":"2025-11-25","kind":"sale","planned":false,"acquired":false,"shares":2000,"price":28.135,"value":56270.0,"ownership":{"direct":false,"nature":"By Balmoral Financial Group LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":32001,"source":{"system":"sec-edgar","filing":"0001753926-25-001831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001831/ownership.xml","form_type":"4"}},{"id":986570,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T17:37:02.000Z","date":"2025-11-25","kind":"sale","planned":false,"acquired":false,"shares":5999,"price":28,"value":167972.0,"ownership":{"direct":false,"nature":"By Balmoral Financial Group LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":34001,"source":{"system":"sec-edgar","filing":"0001753926-25-001831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001831/ownership.xml","form_type":"4"}},{"id":1091067,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-07-08T01:42:40.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":58230,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."}],"balance_after":58230,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":58230},"source":{"system":"sec-edgar","filing":"0001753926-25-001104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001104/ownership.xml","form_type":"4"}},{"id":1091066,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-07-08T01:42:40.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":19108,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 2, 2025, the Reporting Person was granted stock restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 2, 2025, the Reporting Person was granted stock restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":28012,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":19108},"source":{"system":"sec-edgar","filing":"0001753926-25-001104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001104/ownership.xml","form_type":"4"}},{"id":1091804,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-04T01:05:54.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Key Recovery Group LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001753926-25-001079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001079/ownership.xml","form_type":"4"}},{"id":1091803,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-04T01:05:54.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Balmoral Financial Group LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001753926-25-001079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001079/ownership.xml","form_type":"4"}},{"id":1091802,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-04T01:05:54.000Z","date":"2025-07-01","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Key Recovery Group LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":40000,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001753926-25-001079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001079/ownership.xml","form_type":"4"}},{"id":1091801,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-04T01:05:54.000Z","date":"2025-07-01","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Balmoral Financial Group LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":40000,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":92072},"source":{"system":"sec-edgar","filing":"0001753926-25-001079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001079/ownership.xml","form_type":"4"}},{"id":1091800,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-04T01:05:54.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":10,"value":400000.0,"ownership":{"direct":false,"nature":"By Key Recovery Group LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001753926-25-001079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001079/ownership.xml","form_type":"4"}},{"id":1091799,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-04T01:05:54.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":10,"value":400000.0,"ownership":{"direct":false,"nature":"By Balmoral Financial Group LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001753926-25-001079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001079/ownership.xml","form_type":"4"}},{"id":1363124,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-11-15T21:19:00.000Z","date":"2024-11-13","kind":"grant","planned":false,"acquired":true,"shares":24533,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters."}],"balance_after":634752,"derivative":{"exercise_price":0.64,"expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":24533},"source":{"system":"sec-edgar","filing":"0001753926-24-001947","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392624001947/ownership.xml","form_type":"4"}},{"id":1474473,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-19T00:03:45.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":64498,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 64,498 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 64,498 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years."}],"balance_after":610219,"derivative":{"exercise_price":1.3,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":64498},"source":{"system":"sec-edgar","filing":"0001753926-24-001133","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392624001133/ownership.xml","form_type":"4"}},{"id":1580114,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-12T20:05:51.000Z","date":"2024-02-21","kind":"purchase","planned":false,"acquired":true,"shares":16667,"price":6,"value":100002.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the \"Common Stock\") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the \"Common Stock\") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the \"Common Stock\") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the \"Common Stock\") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the \"Common Stock\") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024."}],"balance_after":545721,"source":{"system":"sec-edgar","filing":"0001753926-24-000518","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392624000518/ownership.xml","form_type":"4/A","original_submission_date":"2024-02-21"}},{"id":1621686,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Secured Convertible Promissory Note","published_at":"2024-02-23T22:12:56.000Z","date":"2024-02-21","kind":"exercise","planned":false,"acquired":false,"shares":33136,"ownership":{"direct":false,"nature":"Balmoral Financial Group LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Balmoral Financial Group LLC (\"Balmoral\"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account)."}],"balance_after":0,"derivative":{"exercise_price":4.8,"exercise_date":"2024-02-21","expiration_date":"2024-03-01","underlying":"Common Stock","underlying_shares":6992},"source":{"system":"sec-edgar","filing":"0001753926-24-000372","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392624000372/ownership.xml","form_type":"4"}},{"id":1621685,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Secured Convertible Promissory Note","published_at":"2024-02-23T22:12:56.000Z","date":"2024-02-21","kind":"exercise","planned":false,"acquired":false,"shares":65513.61,"ownership":{"direct":false,"nature":"Balmoral Financial Group LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Balmoral Financial Group LLC (\"Balmoral\"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account)."}],"balance_after":0,"derivative":{"exercise_price":4.8,"exercise_date":"2024-02-21","expiration_date":"2024-02-29","underlying":"Common Stock","underlying_shares":13649},"source":{"system":"sec-edgar","filing":"0001753926-24-000372","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392624000372/ownership.xml","form_type":"4"}},{"id":1621684,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-23T22:12:56.000Z","date":"2024-02-21","kind":"exercise","planned":false,"acquired":true,"shares":6992,"price":4.8,"value":33561.6,"ownership":{"direct":false,"nature":"Balmoral Financial Group LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Balmoral Financial Group LLC (\"Balmoral\"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account)."}],"balance_after":520719,"source":{"system":"sec-edgar","filing":"0001753926-24-000372","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392624000372/ownership.xml","form_type":"4"}},{"id":1621683,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-23T22:12:56.000Z","date":"2024-02-21","kind":"exercise","planned":false,"acquired":true,"shares":13649,"price":4.8,"value":65515.2,"ownership":{"direct":false,"nature":"Balmoral Financial Group LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Balmoral Financial Group LLC (\"Balmoral\"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account)."}],"balance_after":513727,"source":{"system":"sec-edgar","filing":"0001753926-24-000372","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392624000372/ownership.xml","form_type":"4"}},{"id":4602520,"issuer":{"id":108862,"kind":"organization","name":"HUMANIGEN, INC","symbol":"HGEN"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2016-09-15T17:38:00.000Z","date":"2016-09-13","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 12 equal quarterly installments beginning on December 13, 2016."}],"balance_after":100000,"derivative":{"exercise_price":3.38,"expiration_date":"2026-09-12","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001123292-16-002730","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293310/000112329216002730/edgar.xml","form_type":"4"}}]}